GENClinical Trialsglobenewswire

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Sentiment:Positive (70)

Summary

Company Announcement

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 7, 2025 by globenewswire

    Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) | GEN Stock News | Candlesense